Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.Qian Qin, Che‐Kai Tsao, Vaibhav G. Patel et al.|Journal of Clinical Oncology|2020Cited by 16
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysisQian Qin, Che‐Kai Tsao, Amanda Leiter et al.|Discover Oncology|2022Cited by 12
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate CancerNeil J. Shah, William Oh, Vaibhav G. Patel et al.|JNCI Cancer Spectrum|2022Cited by 11
The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.Vaibhav G. Patel, William Oh, Xiaobo Zhong et al.|Journal of Clinical Oncology|2021Cited by 5
Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor TherapyAnish B. Parikh, Che‐Kai Tsao, Xiaobo Zhong et al.|American Journal of Clinical Oncology|2021Cited by 4